Navigation Links
Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
Date:6/3/2010

PASADENA, Calif., June 3 /PRNewswire-FirstCall/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry®, today announced that the Cambridge Planning Board has granted final zoning approval for its transformative life science development, known as the Binney Street Project.  This development, with its crucial adjacency location near Kendall Square, in the heart of East Cambridge, is positioned to be the epicenter of Cambridge's life science industry.

The Binney Street Project is an 11.3-acre development that will consist of approximately 1.72 million square feet of office/laboratory space and other mixed uses.  It will include a mixed mode transportation center and more than two acres of public open space for the East Cambridge community.  Once completed, the Project will have five highly sustainable state-of-the-art life science facilities in addition to the preservation of existing historic buildings.  All buildings will be LEED certifiable, employing state-of-the-art design and technology featuring sustainable operations including high-efficiency mechanical systems, rooftop storm water management and water-efficient landscaping.  This innovative development, in the heart of the renowned Kendall Square district, will provide convenient access to leading research and academic institutions including Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, the Broad Institute and Harvard University.  

"The Binney Street Project is one of the most important developments of its kind and will further enhance Cambridge's position as a world leading center for life science research and development," said Tom Andrews, Senior Vice President and Regional Market Director, Alexandria Real Estate Equities, Inc.  "We have worked closely with the City of Cambridge on this project and look forward to moving forward with the development of a truly unique, world-class life science cluster that will attract leading research organizations, pharmaceutical and emerging biopharmaceutical companies to an already vibrant broad and diverse life science community."

Alexandria Real Estate Equities, Inc. has a dominant presence in the Cambridge market, with more than 2.1 million square feet of office/laboratory space and more than 60 client-tenants.  Alexandria's Technology Square life science cluster is one of the world's leading destinations for the industry.  Within the Cambridge market, Alexandria includes among its client tenants such industry leaders as GlaxoSmithKline, Inc., Massachusetts Institute of Technology, Novartis AG, Pfizer Inc., Biogen Idec, Dyax Corp., Alnylam Pharmaceuticals, Inc. and Thermo Fisher Scientific Inc.

About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest owner and pre-eminent first-in-class REIT and leading provider of high-quality environmentally sustainable real estate, technical infrastructure, and services to the broad and diverse life science industry focused in the leading life science clusters.  Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biotechnology, medical device, product, service and translational entities, renewable energy entities, as well as government agencies.  Alexandria's operating platform is based on the principle of "clustering," with assets and operations located in key life science markets.  Our asset base approximates 12.7 million rentable square feet (including spaces undergoing active redevelopment and properties undergoing ground-up development).

This press release contains forward-looking statements, including earnings guidance, within the meaning of the federal securities laws. Actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in our Annual Report on Form 10-K and our other periodic reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Alexandria Real Estate Equities, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
2. Alexandria Real Estate Equities, Inc. Provides Update
3. Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock
4. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
5. Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock
6. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
7. Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results
8. Deals keep Coming in Medical real Estate
9. Millions Flowing into Medical Real Estate
10. Life Sciences Real Estate Outperforming Other Sectors
11. Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):